Biologic therapies in Primary Sjögren's Syndrome

Current Pharmaceutical Biotechnology

Volumn 13, Issue 10, 2012, Pages 1997-2008

  Bowman, S J ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biologic therapies; Clinical trials; Pathogenesis; Primary Sj gren's syndrome; Rituximab

Indexed keywords

ADALIMUMAB; ATACICEPT; AZATHIOPRINE; CEVIMELINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EPRATUZUMAB; ETANERCEPT; GALIXIMAB; HYDROXYCHLOROQUINE; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INOTUZUMAB OZOGAMICIN; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PILOCARPINE; PLACEBO; PREDNISOLONE; RITUXIMAB; TOSITUMOMAB; TRU 015; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE;

ARTHRALGIA; ARTHRITIS; ARTICLE; BIOLOGICAL THERAPY; CYTOKINE RELEASE SYNDROME; DRUG COST; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEPATITIS; HUMAN; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERSTITIAL LUNG DISEASE; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MELANOMA; MONOTHERAPY; NEUROPATHY; NONHODGKIN LYMPHOMA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; RHEUMATOID ARTHRITIS; SALIVARY GLAND DISEASE; SIDE EFFECT; SJOEGREN SYNDROME; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL AGENTS; CHEMOKINES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84861689992     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112802273263     Document Type: Article

References (118)

1. thedition (Koopman, W.J. Moreland, L.W. eds). Lippincott Williams & Wilkins, 2005, chap: 78 pp 1681-1705.
2. Segal, B.; Bowman, S.J.; Fox, P.C.; Vivino, F.B.; Murukutla, N.; Brodscholl, J.; Ogale, S.; McLean, L. Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health. Qual. Life. Outcomes., 2009, 27, 7 46.
3. Kruize, A.A.; Hené, R.J.; van der Heide, A.; Bodeutsch, C.; de Wilde, P.C.; van Bijsterveld, O.P.; de Jong, J.; Feltkamp, T.E.; Kater, L.; Bijlsma, J.W.; Long-term followup of patients with Sjögren's syndrome. Arthritis. Rheum., 1996, 39(2), 297-303.
4. Voulgarelis, M.; Dafni, U.G.; Isenberg, D.A.; Moutsopoulos, H.M. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis. Rheum., 1999, 42(8), 1765-1772.
5. Theander, E.; Henriksson, G.; Ljungberg, O.; Mandl, T.; Manthorpe, R.; Jacobsson, L.T. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis., 2006, 65(6), 796-803.
6. Bowman, S.J.; Ibrahim, G.H.; Holmes, G.; Hamburger, J.; Ainsworth, J.R. Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK. Scand J. Rheumatol. 2004, 33(1), 39-43.
7. Callaghan, R.; Prabu, A.; Allan, R.B.; Clarke, A.E.; Sutcliffe, N.; Pierre, Y.S.; Gordon, C.; Bowman, S.J. The UK Sjögren's Interest Group. Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. Rheumatology (Oxford)., 2007, 46(1),105-111.
8. Bowman, S.J.; St. Pierre, Y.; Sutcliffe, N.; Isenberg, D.A.; Goldblatt, F.; Price, E.; Hamburger, J.; Richards, A.; Rauz, S.; Regan, M.; Rigby, S.; Jones, A.; Mulherin, M.; Clarke, A.E. Estimating indirect costs in primary Sjögren's syndrome. J. Rheumatol., 2010, 37(5), 1010-1015.
9. Sall, K.; Stevenson, O.D.; Mundorf, T.K.; Reis, B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology, 2000, 107(4), 631-639.
10. Vivino, F.B.; Al-Hashimi, I.; Khan, Z.; LeVeque, F.G.; Salisbury, P.L.; Tran-Johnson, T.K.; Muscoplat, C.C.; Trivedi, M.; Goldlust, B;. Gallagher, S.C. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med., 1999, 159(2), 174-181.
11. Fife, R.S.; Chase, W.F.; Dore, R.K.; Wiesenhutter, C.W.; Lockhart, P.B.; Tindall, E.; Suen, J.Y. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch. Intern. Med., 2002, 162(11), 1293-1300.
12. Fox, P.C.; Datiles, M.; Atkinson, J.C.; Macynski, A.A.; Scott, J.; Fletcher, D.; Valdez, I.H.; Kurrasch, R.H.; Delapenha, R.; Jackson, W. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin. Exp. Rheumatol., 1993, 11(2), 149-156.
13. Price, E. J;. Rigby, S.P.; Clancy, U.; Venables, P.J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J. Rheumatol., 1998, 25(5), 896-899.
14. Skopouli, F.N.; Jagiello, P.; Tsifetaki, N.; Moutsopoulos, H.M. Methotrexate in primary Sjögren's syndrome. Clin. Exp. Rheumatol., 1996, 14(5), 555-558.
15. Drosos, A.A.; Skopouli, F.N.; Galanopoulou, V.K.; Kitridou, R.C.; Moutsopoulos, H.M. Cyclosporin a therapy in patients with primary Sjögrens syndrome: results at one year. Scand. J. Rheumatol. Suppl., 1986, 61 246-249.
16. van Woerkom, J.M.; Kruize, A.A.; Geenen, R.; van Roon, E.N.; Goldschmeding, R.; Verstappen, S.M.; van Roon, J.A.; Bijlsma, J.W. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann. Rheum. Dis., 2007, 66(8), 1026-1032.
17. Kruize, A.A.; Hené, R.J.; Kallenberg, C.G.; van Bijsterveld, O.P.; van der Heide, A.; Kater, L.; Bijlsma, J.W. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann. Rheum. Dis., 1993, 52(5), 360-364.
18. Strömbeck, B.E.; Theander, E.; Jacobsson, L.T. Effects of exercise on aerobic capacity and fatigue in women with primary Sjogren's syndrome. Rheumatology (Oxford), 2007, 46(5), 868-871.
19. Willeke, P.; Schlüter, B.; Becker, H.; Schotte, H.; Domschke, W.; Gaubitz, M. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis. Res. Ther., 2007, 9(6), R115.
20. Delalande, S.; de Seze, J.; Fauchais, A.L.; Hachulla, E.; Stojkovic, T.; Ferriby, D.; Dubucquoi, S.; Pruvo, J.P.; Vermersch, P.; Hatron, P.Y. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore), 2004, 83(5), 280-291.
21. Cavalli, F.; Isaacson, P.G.; Gascoyne, R.D.; Zucca, E. Malt lymphomas. Haematol. Am. SocHaematol. Edu. Prog., 2001, 2001 241-258.
22. Marcus, R.; Imrie, K.; Belch, A.; Cunningham, D.; Flores, E.; Catalano, J.; Solal-Celigny, P.; Offner, F.; Walewski, J.; Raposo, J.; Jack, A.; Smith, P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 2005, 105(4), 1417-1423.
23. Mounier, N.; Briere, J.; Gisselbrecht, C.; Emile, J.F.; Lederlin, P.; Sebban, C.; Berger, F.; Bosly, A.; Morel, P.; Tilly, H.; Bouabdallah, R.; Reyes, F.; Gaulard, P.; Coiffier, B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood, 2003, 101(11), 4279-4284.
24. Voulgarelis, M.; Giannouli, S.; Tzioufas, A.G.; Moutsopoulos, H.M. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis., 2006, 65(8), 1033-1037.
25. Voulgarelis, M.; Dafni, U.G.; Isenberg, D.A.; Moutsopoulos, H.M. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis. Rheum., 1999, 42(8), 1765-1772.
26. Pijpe, J.; van Imhoff, G.W.; Spijkervet, F.K.; Roodenburg, J.L.; Wolbink, G.J.; Mansour, K.; Vissink, A.; Kallenberg, C.G.; Bootsma, H. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis. Rheum., 2005, 52(9), 2740-2750.
27. Meijer, J.M.; Pijpe, J.; Vissink, A.; Kallenberg, C.G.; Bootsma, H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann. Rheum. Dis., 2009, 68(2), 284-285.
28. Seror, R.; Sordet, C.; Guillevin, L.; Hachulla, E.; Masson, C.; Ittah, M.; Candon, S.; Le Guern, V.; Aouba, A.; Sibilia, J.; Gottenberg, J.E.; Mariette, X. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann. Rheum. Dis., 2007, 66(3), 351-357.
29. Salliot, C.; Dougados, M.; Gossec, L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann. Rheum. Dis. 2009, 68(1), 25-32.
30. Furst, D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis. Rheum., 2010, 39(5), 327-346.
31. Kausar, F.; Mustafa, K.; Sweis, G.; Sawaqed, R.; Alawneh, K.; Salloum, R.; Badaracco, M.; Niewold, T.B.; Sweiss, N.J. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert. Opin. Biol. Ther., 2009, 9(7), 889-895.
32. Molloy, E.S.; Calabrese, L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis. Rheum., 2009, 60(12), 3761-3765.
33. Carson, K.R.; Evens, A.M.; Richey, E.A.; Habermann, T.M.; Focosi, D.; Seymour, J.F.; Laubach, J.; Bawn, S.D.; Gordon, L.I.; Winter, J.N.; Furman, R.R.; Vose, J.M.; Zelenetz, A.D.; Mamtani, R.; Raisch, D.W.; Dorshimer, G.W.; Rosen, S.T.; Muro, K.; Gottardi-Littell, N.R.; Talley, R.L.; Sartor, O.; Green, D.; Major, E.O.; Bennett, C.L. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood, 2009, 113(20), 4834-4840.
34. Bowman, S.J.; Booth, D.A.; Platts, R.G. The UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheumatology (Oxford), 2004, 43(6), 758-764.
35. Bowman, S.J.; Booth, D.A.; Platts, R.G.; Field, A.; Rostron, J.; the UK Sjögren's Interest Group. Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome. J. Rheumatol., 2003, 30(6), 1259-1266.
36. Bowman, S.J.; Hamburger, J;. Richards, A.; Barry, R.J.; Rauz, S. Patient-reported outcomes in primary Sjogren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort--Sicca Symptoms Inventory. Rheumatology (Oxford), 2009, 48(2), 140-143.
37. Seror, R.; Ravaud, P.; Bowman, S.; Baron, G.; Tzioufas, A.; Theander, E.; Gottenberg, J.E.; Bootsma, H.; Mariette, X.; Vitali, C. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann. Rheum. Dis., 2010, 69(6), 1103-1109.
38. Vitali, C.; Palombi, G.; Baldini, C.; Benucci, M.; Bombardieri, S.; Covelli, M.; Del Papa, N.; De Vita, S.; Epis, O.; Franceschini, F.; Gerli, R.; Govoni, M.; Bongi, S.M.; Maglione, W.; Migliaresi, S.; Montecucco, C.; Orefice, M.; Priori, R.; Tavoni, A.; Valesini, G. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis. Rheum., 2007, 56(7), 2223-2231.
39. Bowman, S.J.; Sutcliffe, N.; Isenberg, D.A.; Goldblatt, F.; Adler, M.; Price, E.; Canavan, A.; Hamburger, J.; Richards, A.; Rauz, S.; Regan, M.; Gadsby, K.; Rigby, S.; Jones, A.; Mathew, R.; Mulherin, D.; Stevenson, A.; Nightingale, P. Sjögren's Systemic Clinical Activity Index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. Rheumatology (Oxford), 2007, 46(12), 1845-1851.
40. Barry, R.J.; Sutcliffe, N.; Isenberg, D.A.; Price, E.; Goldblatt, F.; Adler, M.; Canavan, A.; Hamburger, J.; Richards, A.; Regan, M.; Gadsby, K.; Rigby, S.; Jones, A.; Mathew, R.; Mulherin, D.; Stevenson, A.; Nightingale, P.; Rauz, S.; Bowman, S.J. The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome. Rheumatology (Oxford), 2008, 47(8), 1193-1198.
41. Bron, A.J. Diagnosis of dry eye. Surv. Ophthalmol., 2001, 45(Suppl 2), S221-226.
42. Gibbons, L.J.; Hyrich, K.L. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs, 2009, 23(2), 111-124.
43. Jilaveanu, L.B.; Aziz, S.A.; Kluger, H.M. Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol., 2009, 27(6), 614-625.
44. Forde, K.A.; Reddy, K.R. Hepatitis C virus infection and immunomodulatory therapies. Clin. Liver Dis., 2009, 13(3), 391-401.
45. Looney, R.J. Will targeting B cells be the answer for Sjögren's syndrome? Arthritis. Rheum., 2007, 56(5), 1371-1377.
46. Salomonsson, S.; Jonsson, M.V.; Skarstein, K.; Brokstad, K.A.; Hjelmström, P.; Wahren-Herlenius, M.; Jonsson, R. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis. Rheum., 2003, 48(11), 3187-3201.
47. Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; Pillemer, S.R.; Talal, N.; Weisman, M.H. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis., 2002, 61(6), 554-558.
48. Pers, J.O.; Devauchelle, V.; Daridon, C.; Bendaoud, B.; Le Berre, R.; Bordron, A;. Hutin, P.; Renaudineau, Y.; Dueymes, M.; Loisel, S.; Berthou, C.; Saraux, A.; Youinou, P. BAFFmodulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis. Rheum., 2007, 56(5), 1464-1477.
49. Pijpe, J.; Meijer, J.M.; Bootsma, H.; van der Wal, J.E.; Spijkervet, F.K.L.; Kallenberg, C.G.M.; Vissink, A.; Ihrler, S. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis. Rheum., 2009, 60(11), 3251-3256.
50. Leandro, M.J.; Edwards, J.C.; Cambridge, G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis., 2002, 61(10), 883-888.
51. Gottenberg, J.E.; Guillevin, L.; Lambotte, O.; Combe, B.; Allanore, Y.; Cantagrel, A.; Larroche, C.; Soubrier, M.; Bouillet, L.; Dougados, M.; Fain, O.; Farge, D.; Kyndt, X.; Lortholary, O.; Masson, C.; Moura, B.; Remy, P.; Thomas, T.; Wendling, D.; Anaya, J.M.; Sibilia, J.; Mariette, X.; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis., 2005, 64(6), 913-920.
52. Devauchelle-Pensec, V.; Pennec, Y.; Morvan, J.; Pers, J.O.; Daridon, C.; Jousse-Joulin, S.; Roudaut, A.; Jamin, C.; Renaudineau, Y.; Roué, I.Q.; Cochener, B.; Youinou, P.; Saraux, A. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis. Care. Res., 2007, 57(2), 310-317.
53. Levesque, M.C.; Luning Prak, N.; St. Clair, E.W.; Meng, W.; Du, Y.Z.; McNair, P.D.; Whitesides, J.F.; Kelsoe, G.; Reddy, S.; Cohen, P.L. Longitudinal analysis of lymphocyte subsets in patients with primary Sjogren's syndrome (pSS) treated with rituximab: Results from an open-label clinical trial. Arthritis. Rheum., 2007, 56(9) (Suppl), S445.
54. Dass, S.; Bowman, S.J.; Vital, E.M.; Ikeda, K.; Pease, C.T.; Hamburger, J.; Richards, A.; Rauz, S.; Emery, P. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis., 2008, 67(11), 1541-1544.
55. Steinfeld, S. D;. Tant, L.; Burmester, G.R.; Teoh, N.K.; Wegener, W.A.; Goldenberg, D.M.; Pradier, O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res. Ther., 2006, 8(4), R129.
56. Moore, P.A.; Belvedere, O.; Orr, A.; Pieri, K.; LaFleur, D.W.; Feng, P.; Soppet, D.; Charters, M.; Gentz, R.; Parmelee, D.; Li, Y.; Galperina, O.; Giri, J.; Roschke, V.; Nardelli, B.; Carrell, J.; Sosnovtseva, S.; Greenfield, W.; Ruben, S.M.; Olsen, H.S.; Fikes, J;. Hilbert, D.M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285(5425), 260-263.
57. Schneider, P.; MacKay, F.; Steiner, V.; Hofmann, K.; Bodmer, J.L.; Holler, N.; Ambrose, C.; Lawton, P.; Bixler, S.; Acha-Orbea, H.; Valmori, D.; Romero, P.; Werner-Favre, C.; Zubler, R.H.; Browning, J.L.; Tschopp, J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med., 1999, 189(11), 1747-1756.
58. Mackay, F.; Woodcock, S.A.; Lawton, P.; Ambrose, C.; Baetscher, M.; Schneider, P.; Tschopp, J.; Browning, J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med., 1999, 190(11), 1697-710.
59. Mariette, X.; Roux, S.; Zhang, J.; Bengoufa, D.; Lavie, F.; Zhou, T.; Kimberly, R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann. Rheum. Dis., 2003, 62(2), 168-171.
60. Pers, J.O.; Daridon, C.; Devauchelle, V.; Jousse, S.; Saraux, A.; Jamin, C.; Youinou, P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. N. Y. Acad. Sci., 2005, 1050 34-39.
61. Jonsson, M.V.; Szodoray, P.; Jellestad, S.; Jonsson, R.; Skarstein, K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J. Clin. Immunol., 2005, 25(3), 189-201.
62. Nossent, J.C.; Lester, S.; Zahra, D.; Mackay, C.R.; Rischmueller, M. Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. Rheumatology (Oxford), 2008, 47(9), 1311-1316.
63. Lavie, F.; Miceli-Richard, C.; Ittah, M.; Sellam, J.; Gottenberg, J.E.; Mariette, X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand. J. Immunol., 2008, 67(2), 185-192.
64. Szodoray, P.; Alex, P.; Jonsson, M.V.; Knowlton, N.; Dozmorov, I.; Nakken, B.; Delaleu, N.; Jonsson, R.; Centola, M. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin. Immunol., 2005, 117(2), 168-176.
65. Ittah, M.; Miceli-Richard, C.; Gottenberg, J-E.; Lavie, F.; Lazure, T.; Ba, N.; Sellam, J.; Lepajolec, C.; Mariette, X. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis. Res. Ther., 2006, 8(2), R51.
66. Daridon, C.; Devauchelle, V.; Hutin, P.; Le Berre, R.; Martins-Carvalho, C.; Bendaoud, B.; Dueymes, M.; Saraux, A.; Youinou, P.; Pers, J.O. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis. Rheum., 2007, 56(4),1134-1144.
67. Qian, Y.; Giltiay, N.; Xiao, J.; Wang, Y.; Tian, J.; Han, S.; Scott, M.; Carter, R.; Jorgensen, T.N.; Li, X. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren's syndrome. Eur. J. Immunol., 2008, 38(8), 2219-2128.
68. Lavie, F.; Miceli-Richard, C.; Ittah, M.; Sellam, J.; Gottenberg, J.E.; Mariette, X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis., 2007, 66(5), 700-703.
69. Quartuccio, L.; Fabris, M.; Moretti, M.; Barone F.; Bombardieri, M.; Rupolo, M.; Lombardi, S.; Pitzalis, C.; Beltrami, C.A.; Curcio, F.; De Vita, S. Resistance to rituximab therapy and local BAFF overexpression in sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open. Rheumatol. J., 2008, 2 38-43.
70. Wallace, D.J.; Stohl, W.; Furie, R.A.; Lisse, J.R.; McKay, J.D.; Merrill, J.T.; Petri, M.A.; Ginzler, E.M.; Chatham, W.W.; McCune, W.J.; Fernandez, V.; Chevrier, M.R.; Zhong, Z.J.; Freimuth, W.W. A phase II, randomized, double-blind, placebo-controlled, doseranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis. Rheum., 2009, 61(9), 1168-1178.
71. Pena-Rossi, C.; Nasonov, E.; Stanislav, M.; Yakusevich, V.; Ershova, O.; Lomareva, N.; Saunders, H.; Hill, J.; Nestorov, I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus, 2009, 18(6), 547-555.
72. Ittah, M.; Miceli-Richard, C.; Gottenberg, J.E.; Sellam, J.; Eid, P.; Lebon, P.; Pallier, C.; Lepajolec, C.; Mariette, X. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR-and type-I IFN-dependent and-independent pathways. Eur. J. Immunol., 2008, 38(4), 1058-1064.
73. Mariette, X.; Ravaud, P.; Steinfeld, S.; Baron, G.; Goetz, J.; Hachulla, E.; Combe, B.; Puéchal, X.; Pennec, Y.; Sauvezie, B.; Perdriger, A.; Hayem, G.; Janin, A.; Sibilia, J. Inefficacy of in fliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary sjögren's syndrome (TRIPSS). Arthritis. Rheum., 2004, 50(4), 1270-1276.
74. Sankar, V.; Brennan, M.T.; Kok, M.R.; Leakan, R.A.; Smith, J.A.; Manny, J.; Baum, B.J.; Pillemer, S.R. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum., 2004, 50(7), 2240-2245.
75. Zandbelt, M.M.; de Wilde, P.; van Damme, P.; Hoyng, C.B.; van de Putte, L.; van den Hoogen, F. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J. Rheumatol., 2004, 31(1), 96-101.
76. Mavragani, C.P.; Niewold, T.B.; Moutsopoulos, N.M.; Pillemer, S.R.; Wahl, S.M.; Crow, M.K. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis. Rheum., 2007, 56(12), 3995-4004.
77. Youinou, P.; Jamin, C. The weight of interleukin-6 in B cell-related autoimmune disorders. J. Autoimmun., 2009, 32(3-4), 206-210.
78. Wen, C.L.; Wang, C.R.; Chuang, C.Y.; Chen, C.Y. Increased production of interleukin-6 and autoantibodies in patients with Sjögren's syndrome. Zhonghua. Min. Guo. Wei. Sheng. Wu. Ji. Mian. Yi. Xue. Za. Zhi., 1992, 25(3), 189-195.
79. Fox, R.I.; Kang, H.I.; Ando, D.; Abrams, J.; Pisa, E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J. Immunol., 1994, 152(11), 5532-5539.
80. Boumba, D.; Skopouli, F. N;. Moutsopoulos, H.M. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br. J. Rheum., 1995, 34(4), 326-333.
81. De Vita, S.; Dolcetti, R.; Ferraccioli, G.; Pivetta, B.; De Re, V.; Gloghini, A.; D'Agosto, A.; Bartoli, E.; Carbone, A; Boiocchi, M. Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. J. Rheumatol., 1995, 22(9), 1674-1680.
82. Grisius, M.M.; Bermudez, D.K.; Fox, P.C. Salivary and serum interleukin 6 in primary Sjögren's syndrome. J. Rheumatol., 1997, 24(6), 1089-1091
83. Garcíc-Carrasco, M.; Font, J.; Filella, X.; Cervera, R.; Ramos-Casals, M.; Sisó, A.; Aymamí, A.; Ballesta, A.M.; Ingelmo, M. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin. Exp. Rheumatol., 2001, 19(4), 411-415.
84. Szodoray, P.; Alex, P.; Brun, J.G.; Centola, M.; Jonsson, R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand. J. Immunol., 2004, 59(6), 592-599.
85. Szodoray, P.; Alex, P.; Jonsson, M.V.; Knowlton, N.; Dozmorov, I.; Nakken, B.; Delaleu, N.; Jonsson, R.; Centola, M. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin. Immunol., 2005, 117(2),168-176.
86. Girón-González, J.A.; Baturone, R.; Soto, M.J.; Márquez, M.; Macías, I.; Montes de Oca, M.; Medina, F.; Chozas, N.; García-Pérez, S. Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjögren's syndrome. Cell. Immunol., 2009, 259(1), 56-60.
87. Katsifis, G.E.; Rekka, S.; Moutsopoulos, N.M.; Pillemer, S.; Wahl, S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am. J. Pathol., 2009, 175(3), 1167-1177.
88. Halse, A.; Tengnér, P.; Wahren-Herlenius, M.; Haga, H.; Jonsson, R. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren's syndrome. Scand. J. Immunol., 1999, 49(5), 533-538.
89. Hartkamp, A.; Geenen, R.; Bijl, M.; Kruize, A.A.; Godaert, G.L.; Derksen, R.H. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren's syndrome. Ann. Rheum. Dis., 2004, 63(10), 1335-1337.
90. Baturone, R.; Soto, M.; Marquez, M.; Macias, I.; Montes de Oca, M.; Medina, F.; Chozas, N.; Garcia-Perez, S.; Giron-Gonzalez, J. Health-related quality of life in patients with primary Sjögren's syndrome: relationship with serum levels of proinflammatory cytokines. Scand. J. Rheumatol., 2009, 38(5), 386-389.
91. d'Elia, H.F.; Bjurman, C.; Rehnberg, E.; Kvist, G.; Konttinen, Y.T. Interleukin 6 and its soluble receptor in a central role at the neuroimmunoendocrine interface in Sjogren syndrome: an explanatory interventional study. Ann. Rheum. Dis., 2009, 68(2), 285-286.
92. Tishler, M.; Yaron, I.; Shirazi, I.; Yaron, M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann. Rheum. Dis., 1999, 58(4), 253-225.
93. Nishimoto, N.; Miyasaka, N.; Yamamoto, K.; Kawai, S.; Takeuchi, T.; Azuma, J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis., 2009, 68(10), 1580-1584.
94. Reksten, T.R.; Jonsson, M.V.; Szyszko, E.A.; Brun, J.G.; Jonsson, R.; Brokstad, K.A. Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndrome. Rheumatology (Oxford), 2009, 48(9), 1102-1106.
95. Bave, U.; Nordmark, G.; Lovgren, T.; Ronnelid, J.; Cajander, S.; Eloranta, M.L.; Alm, G.V.; L. Ronnblom, L. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum., 2005, 52(4), 1185-1195.
96. Bombardieri, M.; Barone, F.; Pittoni, V.; Alessandri, C.; Conigliaro, P.; Blades, M.C.; Priori, R.; McInnes, I.B.; Valesini, G.; Pitzalis, C. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arth. Res. Ther., 2004, 6 R447-R456.
97. Sakai, A.; Sugawara, Y.; Kuroishi, T.; Sasano, T.; Sugawara, S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J. Immunol., 2008, 181(4), 2898-906.
98. Vosters, J.L.; Landek-Salgado, M.A.; Yin, H.; Swaim, W.D.; Kimura, H.; Tak, P.P.; Caturegli, P.; Chiorini, J.A. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum., 2009, 60(12), 3633-3641.
99. Holmes, S.; Abrahamson, J.A.; Al-Mahdi, N.; Abdel-Meguid, S.S.; Ho, Y.S. Characterization of the in vitro and in vivo activity of monoclonal antibodies to human IL-18. Hybridoma, 2000, 19(5), 363-367
100. Ship, J.A.; Fox, P.C.; Michalek, J.E.; Cummins, M.J.; Richards, A.B. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J. Interferon Cytokine Res., 1999, 19(8), 943-951.
101. Barone, F.; Bombardieri, M.; Manzo, A.; Blades, M.C.; Morgan, P.R.; Challacombe, S.J.; Valesini, G.; Pitzalis, C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum., 2005, 52 1773-1784.
102. Xanthou, G.; Polihronis, M.; Tzioufas, A.G.; Paikos, S.; Sideras, P.; Moutsopoulos, H.M. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum., 2001, 44(2), 408-418.
103. Salomonsson, S.; Jonsson, M.V.; Skarstein, K.; Brokstad, K.A.; Hjelmström, P.; Wahren-Herlenius, M.; Jonsson, R. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum., 2003, 48(11), 3187-3201.
104. Amft, N.; Curnow, S.J.; Scheel-Toellner, D.; Devadas, A.; Oates, J.; Crocker, J.; Hamburger, J.; Ainsworth, J.; Mathews, J.; Salmon, M.; Bowman, S.J.; Buckley, C.D. Ectopic expression of the B cellattracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. Arthritis Rheum., 2001, 44(11), 2633-2641.
105. Aziz, K.E.; McCluskey, P.J.; Wakefield, D. Expression of selectins (CD62 E, L, P) and cellular adhesion molecules in primary Sjögren's syndrome: questions to immunoregulation. Clin. Immunol. Immunopathol., 1996, 80(1), 55-66.
106. Turkcapar, N.; Sak, S.D.; Saatci, M.; Duman, M.; Olmez, U. Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in salivary glands of patients with Sjögren's syndrome. J. Rheumatol., 2005, 32(6), 1063-1070.
107. Mikulowska-Mennis, A.; Xu, B.; Berberian, J.M.; Michie, S.A. Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am. J. Pathol., 2001, 159(2), 671-681.
108. Cauli, A.; Yanni, G.; Pitzalis, C.; Challacombe, S.; Panayi, G.S. Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis. Ann. Rheum. Dis., 1995, 54(3), 209-215.
109. Nishiyama, T.; Mishima, K.; Obara, K.; Inoue, H.; Doi, T.; Kondo, S.; Saka, M.; Tabunoki, Y.; Hattori, Y.; Kodama, T.; Tsubota, K.; Saito, I. Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjögren's syndrome model mice. Clin. Exp. Immunol., 2007, 149(3), 586-595.
110. Westhovens, R.; Kremer, J.M.; Moreland, L.W.; Emery, P.; Russell, A.S.; Li, T.; Aranda, R.; Becker, J.C.; Qi, K.; Dougados, M. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J. Rheumatol., 2009, 36(4), 736-742.
111. Goules, A.; Tzioufas, A.G.; Manousakis, M.N.; Kirou, K.A.; Crow, M.K.; Routsias, J.G.; Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J. Autoimmun., 2006, 26(3),165-171.
112. Dimitriou, I.D.; Kapsogeorgou, E.K.; Moutsopoulos, H.M.; Manoussakis, M.N. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clin. Exp. Immunol., 2002, 127(2), 386-392
113. Boumpas, D.T.; Furie, R.; Manzi, S.; Illei, G.G.; Wallace, D.J.; Balow, J.E.; Vaishnaw, A.; BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum., 2003, 48(3), 719-727.
114. Kalunian, K.C.; Davis, J.C. Jr.; Merrill, J.T.; Totoritis, M.C.; Wofsy, D.; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2002, 46(12), 3251-3258.
115. Spachidou, M.P.; Bourazopoulou, E.; Maratheftis, C.I.; Kapsogeorgou, E.K.; Moutsopoulos, H.M.; Tzioufas A.G.; Manoussakis, M.N. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin. Exp. Immunol., 2007, 147(3), 497-503.
116. Deshmukh, U.S.; Nandula, S.R.; Thimmalapura, P.R.; Scindia, Y.M.; Bagavant, H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J. Oral. Pathol. Med., 2009, 38(1), 42-47.
117. Kawakami, A.; Nakashima, K.; Tamai, M.; Nakamura, H.; Iwanaga, N.; Fujikawa, K.; Aramaki, T.; Arima, K.; Iwamoto, N.; Ichinose, K.; Kamachi, M.; Ida, H.; Origuchi, T.; Eguchi, K. Toll-like receptor in salivary glands from patients with Sjögren's syndrome: functional analysis by human salivary gland cell line. J. Rheumatol., 2007, 34(5), 1019-1026.
118. Barrat, F.J.; Coffman, R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev., 2008, 223 271-283.